EP3241826A3 - Verfahren zur herstellung einer pyrrolverbindung - Google Patents

Verfahren zur herstellung einer pyrrolverbindung Download PDF

Info

Publication number
EP3241826A3
EP3241826A3 EP17174350.3A EP17174350A EP3241826A3 EP 3241826 A3 EP3241826 A3 EP 3241826A3 EP 17174350 A EP17174350 A EP 17174350A EP 3241826 A3 EP3241826 A3 EP 3241826A3
Authority
EP
European Patent Office
Prior art keywords
compound
pyrrole compound
producing
present
sulfonylpyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17174350.3A
Other languages
English (en)
French (fr)
Other versions
EP3241826B1 (de
EP3241826A2 (de
Inventor
Tomomi Ikemoto
Hideya Mizufune
Toshiaki Nagata
Misayo Sera
Naohiro Fukuda
Takeshi Yamasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to EP21187758.4A priority Critical patent/EP3929187A3/de
Priority to EP19199941.6A priority patent/EP3613734B1/de
Publication of EP3241826A2 publication Critical patent/EP3241826A2/de
Publication of EP3241826A3 publication Critical patent/EP3241826A3/de
Application granted granted Critical
Publication of EP3241826B1 publication Critical patent/EP3241826B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
EP17174350.3A 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung Active EP3241826B1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21187758.4A EP3929187A3 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP19199941.6A EP3613734B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009042975 2009-02-25
PCT/JP2010/052874 WO2010098351A1 (ja) 2009-02-25 2010-02-24 ピロール化合物の製造法
EP10746231.9A EP2402313B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP14152159.1A EP2765130B1 (de) 2009-02-25 2010-02-24 Intermediate für einen Verfahren zur Herstellung von Pyrrolverbindungen

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP14152159.1A Division-Into EP2765130B1 (de) 2009-02-25 2010-02-24 Intermediate für einen Verfahren zur Herstellung von Pyrrolverbindungen
EP14152159.1A Division EP2765130B1 (de) 2009-02-25 2010-02-24 Intermediate für einen Verfahren zur Herstellung von Pyrrolverbindungen
EP10746231.9A Division EP2402313B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP21187758.4A Division EP3929187A3 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP19199941.6A Division EP3613734B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP19199941.6A Division-Into EP3613734B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung

Publications (3)

Publication Number Publication Date
EP3241826A2 EP3241826A2 (de) 2017-11-08
EP3241826A3 true EP3241826A3 (de) 2017-12-06
EP3241826B1 EP3241826B1 (de) 2019-10-30

Family

ID=42665557

Family Applications (5)

Application Number Title Priority Date Filing Date
EP17174350.3A Active EP3241826B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP19199941.6A Active EP3613734B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP14152159.1A Active EP2765130B1 (de) 2009-02-25 2010-02-24 Intermediate für einen Verfahren zur Herstellung von Pyrrolverbindungen
EP21187758.4A Pending EP3929187A3 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP10746231.9A Active EP2402313B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP19199941.6A Active EP3613734B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP14152159.1A Active EP2765130B1 (de) 2009-02-25 2010-02-24 Intermediate für einen Verfahren zur Herstellung von Pyrrolverbindungen
EP21187758.4A Pending EP3929187A3 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung
EP10746231.9A Active EP2402313B1 (de) 2009-02-25 2010-02-24 Verfahren zur herstellung einer pyrrolverbindung

Country Status (8)

Country Link
US (7) US8822694B2 (de)
EP (5) EP3241826B1 (de)
JP (2) JP5628787B2 (de)
KR (2) KR101814357B1 (de)
CN (5) CN102421753B (de)
ES (4) ES2640931T3 (de)
MY (2) MY173940A (de)
WO (1) WO2010098351A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487485B2 (en) 2013-02-28 2016-11-08 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound
CN103965092B (zh) * 2014-04-24 2015-12-02 成都安斯利生物医药有限公司 一种合成2-溴-n-对甲基苯磺酰基吡咯的方法
CN104860923B (zh) * 2015-01-21 2018-01-12 山东康美乐医药科技有限公司 富马酸沃诺拉赞的制备方法
WO2016136963A1 (ja) * 2015-02-27 2016-09-01 彰彦 石川 カケロマイシンおよびその誘導体の製造方法
CN105315258A (zh) * 2015-05-16 2016-02-10 南京海纳医药科技有限公司 富马酸沃诺拉赞多晶型及其制备方法
CN104860926B (zh) * 2015-06-10 2017-06-30 浙江诚意药业股份有限公司 一种富马酸沃诺拉赞的制备方法
CN104926790B (zh) * 2015-06-29 2017-07-07 江苏奥赛康药业股份有限公司 一种高纯度Vonoprazan Fumarate化合物及其中间体、杂质以及它们的制备方法
KR102652511B1 (ko) 2015-06-30 2024-03-28 다케다 야쿠힌 고교 가부시키가이샤 피롤 화합물의 제조 방법
CN106478597A (zh) * 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 富马酸沃诺拉赞单晶及其制备方法和用途
CN105294653B (zh) * 2015-11-16 2017-08-15 山东罗欣药业集团股份有限公司 富马酸沃诺拉赞的制备工艺
CN105440019A (zh) * 2015-12-17 2016-03-30 昆明贵研药业有限公司 一种治疗胃酸疾病药物的制备方法
CN105503828A (zh) * 2015-12-24 2016-04-20 北京康立生医药技术开发有限公司 一种吡咯衍生物的富马酸盐的制备方法
CN106146466A (zh) * 2016-06-30 2016-11-23 珠海赛隆药业股份有限公司（长沙）医药研发中心 富马酸沃诺拉赞中间体、其制备方法和制备富马酸沃诺拉赞的方法
CN106187852B (zh) * 2016-07-07 2019-01-15 江西同和药业股份有限公司 一种富马酸沃诺拉赞中间体的制备方法
CN106243008B (zh) * 2016-08-22 2018-09-04 山东金城生物药业有限公司 富马酸沃诺拉赞中间体5-(2-氟苯基)-1h-吡咯-3-甲醛的制备方法
CN107778207A (zh) * 2016-08-25 2018-03-09 广东东阳光药业有限公司 富马酸沃诺拉赞中间体及其制备方法和用途
CN107793343B (zh) * 2016-09-07 2020-08-07 广东东阳光药业有限公司 一种吡咯化合物的制备方法
CN107162949A (zh) * 2017-07-12 2017-09-15 北京天弘天达医药科技股份有限公司 一种富马酸沃诺拉赞关键中间体及其制备方法
CN107236127A (zh) * 2017-07-21 2017-10-10 张娟 一种复合单体改性导电材料的制备方法
CN107236126A (zh) * 2017-07-21 2017-10-10 张娟 一种高导电复合材料的制备方法
US10207974B1 (en) 2017-12-05 2019-02-19 Chevron Phillips Chemical Company Lp Synthesis of gamma dicarbonyl and pyrrole compounds
CN108503621B (zh) * 2017-12-25 2021-09-14 上海中拓医药科技有限公司 一种富马酸沃诺拉赞的制备方法
WO2019131695A1 (ja) * 2017-12-27 2019-07-04 日本ケミファ株式会社 １－［５－（２－フルオロフェニル）－１－（ピリジン－３－イルスルホニル）－１ｈ－ピロ－ル－３－イル］－ｎ－メチルメタンアミンモノフマル酸塩の製造法
CN110396080B (zh) * 2018-04-24 2022-07-08 广东东阳光药业有限公司 一种富马酸沃诺拉赞代谢物及其氘代物的制备方法
EP3750106A4 (de) * 2018-07-30 2021-09-01 Hewlett-Packard Development Company, L.P. Identifizierung durch neuronale netze von objekten in 360-grad-bildern
CN110272409A (zh) * 2019-03-11 2019-09-24 南京百迪尔生物医药有限公司 一步法合成沃诺拉赞的新方法
CN111018835B (zh) * 2019-12-16 2022-09-20 株洲千金药业股份有限公司 一种沃诺拉赞的纯化方法
CN113511995A (zh) * 2020-04-10 2021-10-19 四川科伦药物研究院有限公司 5-(2-氟苯基)-1h-吡咯-3-甲醛的制备方法
CN112194607A (zh) * 2020-08-27 2021-01-08 河北科博莱特医药科技有限公司 一种5-(2-氟苯基)-1h-吡咯-3-甲醛的合成方法
CN112812099B (zh) * 2021-01-19 2022-04-26 珠海赛隆药业股份有限公司 一种用于治疗消化性溃疡的化合物及其制法和用途
CN113173876B (zh) * 2021-04-16 2022-04-29 南京海纳医药科技股份有限公司 一种富马酸伏诺拉生中间体的制备方法
CN113620930B (zh) * 2021-07-12 2022-08-16 南京烁慧医药科技有限公司 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用
CN113651746A (zh) * 2021-08-16 2021-11-16 杭州煌森生物科技有限公司 一种5-(2-氟苯基)-1h-吡咯-3-甲醛的制备方法
CN113845459B (zh) * 2021-10-14 2023-04-07 山东诚创蓝海医药科技有限公司 一种5-(2-氟苯基)-1h-吡咯-3-甲醛的制备方法
CN114539219A (zh) * 2022-03-17 2022-05-27 日照正济药业有限公司 一种富马酸伏诺拉生的制备方法
CN115232107A (zh) * 2022-07-29 2022-10-25 南京唯创远医药科技有限公司 一种高纯度富马酸伏诺拉生的制备方法
CN116178239B (zh) * 2022-12-30 2024-03-29 山东铂源药业股份有限公司 一种5-（2-氟苯基）-1h-吡咯-3-甲醛的合成方法
CN117647607B (zh) * 2024-01-30 2024-04-26 山东百诺医药股份有限公司 一种同时测定5-(2-氟苯基)-1h-吡咯-3-甲醛中有关物质的hplc检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010098A (en) * 1987-07-29 1991-04-23 American Cyanamid Company Arylpyrrole insecticidal acaricidal and nematicidal agents and methods for the preparation thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK75779A (da) 1978-03-13 1979-09-14 Du Pont 4,5-diaryl-2- (substitueret thio) pyrroler og sulfoxider og sulfoner deraf samt fremgangsmaader til deres fremstilling og anvendelse
US4546099A (en) 1983-07-22 1985-10-08 Ciba-Geigy Corporation N-Aminomethyl-3-phenyl-4-cyanopyrrole derivatives, compositions and use thereof as microbicides
DE3724554A1 (de) 1987-07-24 1989-02-02 Bayer Ag Substituierte 3-arylpyrrole
CN1026206C (zh) * 1987-07-29 1994-10-19 美国氰胺公司 杀虫、杀螨、杀线虫剂芳基吡咯及其组合物的制备方法
EP0358047A3 (de) * 1988-09-08 1991-05-29 American Cyanamid Company Verfahren zur Bekämpfung von phytopathogenen Pilzen
US5101042A (en) * 1990-12-11 1992-03-31 American Cyanamid Company Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds
US5122615A (en) 1990-12-11 1992-06-16 American Cyanamid Company Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds
US5252746A (en) 1990-12-11 1993-10-12 American Cyanamid Company Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds
US5151536A (en) 1990-12-17 1992-09-29 American Cyanamid Company Process for the manufacture of pesticidal 1-(alkoxymethyl) pyrrole compounds
US5449789A (en) 1992-11-30 1995-09-12 American Cyanamid Company Debrominative chlorination of pyrroles
US5480902A (en) * 1993-08-31 1996-01-02 American Cyanamid Company Thienylpyrrole fungicidal agents
US5359090A (en) 1993-12-29 1994-10-25 American Cyanamid Company Alkoxymethylation of pyrroles
US6271392B1 (en) * 1994-10-07 2001-08-07 Rhone-Poulenc Inc. Intermediates useful for the synthesis of 1-arylpyrrole pesticides
JPH10324687A (ja) * 1997-02-19 1998-12-08 Nippon Soda Co Ltd ピロール化合物、製法および農園芸用殺菌剤
CA2425259A1 (en) 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
JP4716996B2 (ja) * 2003-05-26 2011-07-06 武田薬品工業株式会社 スルホピロール
CA2541458C (en) 2003-10-08 2011-09-20 Eli Lilly And Company Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
ES2402362T3 (es) 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
TW200628446A (en) 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
ME00610B (me) * 2005-08-30 2011-12-20 Takeda Pharmaceuticals Co 1 –heterociklilsulfonil, 2 –aminometil, 5– (hetero–) aril supstituisan 1–h–pirol derivati kao inhibitori lučenja kiseline
NZ572202A (en) * 2006-03-27 2012-05-25 Nerviano Medical Sciences Srl Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
JP4888275B2 (ja) 2007-08-08 2012-02-29 三菱電機株式会社 侵入検知装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010098A (en) * 1987-07-29 1991-04-23 American Cyanamid Company Arylpyrrole insecticidal acaricidal and nematicidal agents and methods for the preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEEM GANGJEE ET AL: "Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 38, no. 12, 1 June 1995 (1995-06-01), pages 2158 - 2165, XP002724661, ISSN: 0022-2623, DOI: 10.1021/JM00012A016 *

Also Published As

Publication number Publication date
US20190127324A1 (en) 2019-05-02
CN105524046B (zh) 2019-03-29
WO2010098351A1 (ja) 2010-09-02
KR20110128318A (ko) 2011-11-29
US20200115336A1 (en) 2020-04-16
EP2765130B1 (de) 2017-07-26
US20110306769A1 (en) 2011-12-15
ES2640931T3 (es) 2017-11-07
EP2402313A1 (de) 2012-01-04
EP3613734B1 (de) 2021-08-25
EP3929187A3 (de) 2022-02-16
CN104211618B (zh) 2016-08-17
US10538489B2 (en) 2020-01-21
US20230088365A1 (en) 2023-03-23
JP2014237701A (ja) 2014-12-18
ES2609980T3 (es) 2017-04-25
CN102421753A (zh) 2012-04-18
ES2898438T3 (es) 2022-03-07
EP3241826B1 (de) 2019-10-30
CN104211618A (zh) 2014-12-17
MY173940A (en) 2020-02-28
EP2402313A4 (de) 2013-06-12
CN114835619A (zh) 2022-08-02
EP3241826A2 (de) 2017-11-08
US20140303378A1 (en) 2014-10-09
EP2765130A3 (de) 2014-12-10
JP5628787B2 (ja) 2014-11-19
ES2770027T3 (es) 2020-06-30
EP3929187A2 (de) 2021-12-29
EP2402313B1 (de) 2016-08-24
US8822694B2 (en) 2014-09-02
EP3613734A3 (de) 2020-03-25
US20210070705A1 (en) 2021-03-11
CN108129374A (zh) 2018-06-08
KR101814357B1 (ko) 2018-01-04
US10844011B2 (en) 2020-11-24
JP5819494B2 (ja) 2015-11-24
US10173977B2 (en) 2019-01-08
US9266831B2 (en) 2016-02-23
EP3613734A2 (de) 2020-02-26
CN105524046A (zh) 2016-04-27
EP2765130A2 (de) 2014-08-13
KR101724293B1 (ko) 2017-04-07
KR20170039773A (ko) 2017-04-11
CN102421753B (zh) 2014-12-31
US20180009746A1 (en) 2018-01-11
MY201120A (en) 2024-02-06
US11498898B2 (en) 2022-11-15
JPWO2010098351A1 (ja) 2012-09-06

Similar Documents

Publication Publication Date Title
EP3613734A3 (de) Verfahren zur herstellung einer pyrrolverbindung
EP1947190A4 (de) Verfahren zur herstellung von bernsteinsäure
MY145818A (en) Process for producing ethylene
PL2235194T3 (pl) Sposób fermentacyjnego wytwarzania 1,5- diaminopentanu
EP2787083A3 (de) Effiziente Herstellung von Peptiden
WO2008076747A3 (en) Processes of producing fermentation products
EP2783573A3 (de) Milch und milchzugehörige Produkte mit langer Haltbarkeit und Verfahren und Milchverarbeitungsanlage zu deren Herstellung
MX2011004324A (es) Proceso novedoso para la preparacion de derivados de aminoacidos.
UA106040C2 (uk) Синтез ефірів або тіоефірів адипату
MY158251A (en) Method for the preparation of nalmefene hydrochloride
EP2248805A3 (de) Verfahren zur Herstellung von Bosentan, dessen polymorphe Formen und Salze
EP2388261A3 (de) Verbessertes Verfahren zur Herstellung eines Carbapenems mithilfe von Carbapenem-Zwischenprodukten und Wiedergewinnung von Carbapenem
EP1900821A4 (de) Verfahren zur herstellung von l-aminosäure
TW200728248A (en) Process for producing propylene
EP3444238A3 (de) Verfahren zur herstellung von difluormethylenverbindung
MX2009005896A (es) Proceso y aparato para preparar metacrilatos de alquilo.
WO2004085349A3 (en) Production of 5-methyl-1-hydrocarbyl-2-pyrrolidone by reductive amination of levulinic acid
TW200734326A (en) Crystalline forms of dolasetron base and processes for preparation thereof
EP2394979A8 (de) Zwischenprodukt von cilastatin und verfahren zu dessen herstellung
EP2669265A3 (de) Verbessertes Verfahren zur Herstellung eines Dipeptidyl-Peptidase-IV-Hemmers und eines Zwischenprodukts
WO2009001372A3 (en) A novel process for the preparation of pregabalin
WO2009084039A3 (en) Process for producing 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol
WO2010113182A8 (en) Intermediates in the preparation of 1,4-diphenyl azetidinone
EP1870476A4 (de) Verfahren zur herstellung von aminosäure
WO2010122575A3 (en) Process for the preparation of pure paliperidone

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 2402313

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2765130

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/12 20060101AFI20171031BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180531

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180712

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190520

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2402313

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2765130

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1195990

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010061781

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200130

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200302

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200131

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200130

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200229

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2770027

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010061781

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1195990

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200731

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200224

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230119

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230120

Year of fee payment: 14

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240301

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240123

Year of fee payment: 15

Ref country code: GB

Payment date: 20240123

Year of fee payment: 15

Ref country code: CH

Payment date: 20240301

Year of fee payment: 15